External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

External broker reports(aggregated public sources)

Motilal Oswal Financial Services Limited

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Glaxosmithkline Pharmaceuticals / Equity Bottom-Up

<div><ul><li>Slower offtake witnessed in the Vaccine segment - GLXO delivered a lower-than-expected performance in 4QFY22. Subdued YoY growth in sales and higher raw material cost affected profitability.</li></ul><div><ul><li>One-off tax provision leads to a quarterly loss - <span style="font-size: var(--content-font-size);">Revenue was up 9% YoY to INR8.1b (est. of INR9.2b).</span></li></ul><div><ul><li>Key takeaways - <span style="font-size: var(--content-font-size);">Secondary sales data from AIOCD indicates that Pain therapy/Anti-Infective/ Dermatology (~12%/~25%/~28% of overall sales) saw a growth of ~39%/ 21%/5% YoY in 4QFY22, driving the outperformance against IPM.</span></li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Slower offtake witnessed in the Vaccine segment - GLXO delivered a lower-than-expected performance in 4QFY22. Subdued YoY growth in sales and higher raw material cost affected profitability.One-off tax provision leads to a quarterly loss - Revenue was up 9% YoY to INR8.1b (est. of INR9.2b).Key takeaways - Secondary sales data from AIOCD indicates that Pain therapy/Anti-Infective/ Dermatology (~12%/~25%/~28% of overall sales) saw a growth of ~39%/ 21%/5% YoY in 4QFY22, driving the outperformance against IPM.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

GSK Pharma - Muted 4QFY22; Focus Remains on Key Brands to Revitalize Growth

<p>Revenue grew 22% YoY to INR7.9b (est. INR8.1b), led by Dermatology, AntiInfectives, and Pain/Analgesics segment. Gross margin expanded by 40bp YoY to 61.7% due to better product mix. EBITDA margin expanded at a higher rate (160bp YoY) to 19% (est. 21.5%) due to better operating leverage, with lower employee cost (down 220bp YoY as a percentage of sales), partially offset by higher other opex (+100bp...</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Revenue grew 22% YoY to INR7.9b (est. INR8.1b), led by Dermatology, AntiInfectives, and Pain/Analgesics segment. Gross margin expanded by 40bp YoY to 61.7% due to better product mix. EBITDA margin expanded at a higher rate (160bp YoY) to 19% (est. 21.5%) due to better operating leverage, with lower employee cost (down 220bp YoY as a percentage of sales), partially offset by higher other opex (+100bp...Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Below expectations as margins disappoint; cut estimates 8
%/7
%

India

Glaxosmithkline Pharmaceuticals Ltd. manufactures and distributes a wide variety of pharmaceutical drugs, veterinary products and laboratory chemicals. The Company's products include "Phexin" capsules, "Betnesol" tablets and injections, "Becoride" asthma treatment, "Betnovate" ointment, "Cetzine" antihistamine, "Zucox" and "Rizap" anti-tuberculosis products.

Glaxosmithkline Pharmaceuticals (GLXO IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GSK Pharma - Muted 4QFY22; Focus Remains on Key Brands to Revitalize Growth

GLXO delivered a lower-than-expected performance in 4QFY22. Subdued YoY growth in sales and higher raw material cost affected profitability.

Motilal Oswal

Below expectations as margins disappoint; cut estimates 8 %/7 %

Revenue grew 22% YoY to INR7.9b (est. INR8.1b), led by Dermatology, AntiInfectives, and Pain/Analgesics segment. Gross margin expanded by 40bp YoY...

Motilal Oswal